Consolidated Planning Corp Has $1.03 Million Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Consolidated Planning Corp lifted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 188.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,140 shares of the medical instruments supplier’s stock after purchasing an additional 2,051 shares during the quarter. Consolidated Planning Corp’s holdings in West Pharmaceutical Services were worth $1,029,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. State Street Corp grew its position in shares of West Pharmaceutical Services by 0.3% in the 3rd quarter. State Street Corp now owns 3,214,448 shares of the medical instruments supplier’s stock valued at $964,850,000 after purchasing an additional 10,060 shares during the period. Geode Capital Management LLC grew its position in shares of West Pharmaceutical Services by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,740,183 shares of the medical instruments supplier’s stock valued at $520,569,000 after purchasing an additional 12,850 shares during the period. Van ECK Associates Corp grew its position in shares of West Pharmaceutical Services by 5,074.0% in the 4th quarter. Van ECK Associates Corp now owns 689,493 shares of the medical instruments supplier’s stock valued at $225,851,000 after purchasing an additional 676,167 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of West Pharmaceutical Services by 21.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 683,350 shares of the medical instruments supplier’s stock valued at $205,114,000 after purchasing an additional 122,361 shares during the period. Finally, FMR LLC grew its position in shares of West Pharmaceutical Services by 199.4% in the 3rd quarter. FMR LLC now owns 595,775 shares of the medical instruments supplier’s stock valued at $178,828,000 after purchasing an additional 396,780 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on WST shares. StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Tuesday. Bank of America upped their price target on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Citigroup started coverage on West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target for the company. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and upped their price target for the stock from $350.00 to $390.00 in a research report on Thursday, December 12th. Finally, Wolfe Research started coverage on West Pharmaceutical Services in a research report on Friday, December 13th. They set a “peer perform” rating for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $403.75.

West Pharmaceutical Services Trading Up 0.2 %

NYSE WST opened at $323.06 on Thursday. The company has a market cap of $23.40 billion, a PE ratio of 47.93, a PEG ratio of 19.31 and a beta of 1.01. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $408.88. The stock has a 50 day moving average of $332.39 and a 200-day moving average of $315.13.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, February 11th. Stockholders of record on Friday, February 7th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend was Friday, February 7th. West Pharmaceutical Services’s payout ratio is presently 12.46%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.